COUR Pharma

Home
COUR Pharma

Reprogramming the immune system to restore health in people suffering from autoimmune diseases

21/09/2022

An excellent time enjoying the Chicago skyline with our incredible team at COUR!

08/01/2022

COUR Pharmaceuticals, a biotechnology company developing novel immune-modifying nanoparticles to treat immune disorders (CNPs), today announced that the first patient has been dosed in the Company’s first-in-human proof-of-concept (Phase 1b/2a) of its lead candidate, CNP-201, for the treatment of peanut allergy.

Chicago, Ill. (January 8th, 2022) – COUR Pharmaceuticals, a biotechnology company developing novel immune-modifying nanoparticles to treat immune disorders (CNPs), today announced that the first patient has been dosed in the Company’s first-in-human proof-of-concept (Phase 1b/2a) of its lead can...

16/04/2021

COUR’s intracellular T-cell reprograming leads to a reduction to anti-drug and neutralizing antibodies.

16/04/2021

Congratulations to the team at COUR for driving innovation in Celiac Disease!

"TAK-101 was well tolerated and prevented gluten-induced immune activation in Celiac Disease. The findings from the present clinical trial suggest that antigen-specific tolerance was induced and represent a novel approach translatable to other immune-mediated diseases"

In celiac disease (CeD), gluten induces immune activation, leading to enteropathy. TAK-101, gluten protein (gliadin) encapsulated in negatively charged poly(dl-lactide-co-glycolic acid) nanoparticles, is designed to induce gluten-specific tolerance.

Address

Website

https://courpharma.com/

Alerts

Be the first to know and let us send you an email when COUR Pharma posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Shortcuts

Want your practice to be the top-listed Clinic?

Country:

City:

21/09/2022

08/01/2022

16/04/2021

16/04/2021

Address

Website

Alerts

Shortcuts

Share